These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1670739)

  • 21. Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients.
    Repo-Tiihonen E; Eloranta A; Hallikainen T; Tiihonen J
    Neuropsychobiology; 2005; 51(4):173-6. PubMed ID: 15870506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia.
    Qurashi I; Collins JD; Chaudhry IB; Husain N
    J Psychopharmacol; 2014 Jul; 28(7):707-8. PubMed ID: 24646811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between delay in initiating clozapine and symptomatic improvement.
    Yada Y; Yoshimura B; Kishi Y
    Schizophr Res; 2015 Oct; 168(1-2):585-6. PubMed ID: 26255084
    [No Abstract]   [Full Text] [Related]  

  • 24. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reply: Suicidality in Huntington's Disease: Distinguishing lithium from other psychotropic medications.
    Moulton CD; Hopkins CW; Bevan-Jones WR
    Mov Disord; 2015 Sep; 30(10):1438-9. PubMed ID: 26010142
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients.
    Kim JS; Kornhuber HH; Holzmüller B; Schmid-Burgk W; Mergner T; Krzepinski G
    Arch Psychiatr Nervenkr (1970); 1980; 228(1):7-10. PubMed ID: 6104477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
    J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of zuclopenthixol in the treatment of aggression in Huntington's disease.
    Tibrewal P; Bastiampillai T; Dhillon R; Cheng R; Fonseka HT
    Asian J Psychiatr; 2017 Apr; 26():152-153. PubMed ID: 28483083
    [No Abstract]   [Full Text] [Related]  

  • 29. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea.
    Piolti R; Appollonio I; Perego M; Pozzi C; Rovati L; Ferrarese C; Frattola L
    Eur Neurol; 1995; 35(6):344-8. PubMed ID: 8591802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C; Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors.
    Ford MF
    Br J Psychiatry; 1986 Nov; 149():654-6. PubMed ID: 2949793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
    Zink M; Mase E; Dressing H
    Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.
    Girotti F; Carella F; Scigliano G; Grassi MP; Soliveri P; Giovannini P; Parati E; Caraceni T
    J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):848-52. PubMed ID: 6147393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmenting strategies in clozapine-resistant schizophrenia.
    Remington G; Saha A; Chong SA; Shammi C
    CNS Drugs; 2006; 20(2):171. PubMed ID: 16478292
    [No Abstract]   [Full Text] [Related]  

  • 35. Pregnancy of a patient treated with clozapine.
    Dickson RA; Hogg L
    Psychiatr Serv; 1998 Aug; 49(8):1081-3. PubMed ID: 9712217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine for Treatment-Resistant Schizophrenia.
    Manu P; Grudnikoff E
    Am J Ther; 2016; 23(5):e1133-4. PubMed ID: 27603450
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
    Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
    Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Practical aspects of drug resistance in schizophrenia].
    Jarema M; Kucińska M
    Psychiatr Pol; 2000; 34(5):721-40. PubMed ID: 11202015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clozapine versus typical neuroleptic medication for schizophrenia.
    Wahlbeck K; Cheine M; Essali MA
    Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'.
    Adesanya A; Pantelis C
    Aust N Z J Psychiatry; 2000 Jun; 34(3):533-4. PubMed ID: 10881988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.